MID-TERM EFFICACY OF DUPILUMAB IN CHILDREN AGED ≥ 36 MONTHS TO < 12 YEARS WITH ATOPIC DERMATITIS: A CASE SERIES

MLA

Melgosa Ramos, Fj, et al. “Mid-Term Efficacy of Dupilumab in Children Aged ≥ 36 Months to < 12 Years with Atopic Dermatitis: A Case Series.” Actas Dermo-Sifiliográficas, no. Preprints, Jan. 2024. EBSCOhost, https://doi.org/10.1016/j.ad.2023.04.042.

APA

Melgosa Ramos, F., Corpas, T. D., Jiménez, S. M., & Puchades, A. M. (2024). Mid-Term Efficacy of Dupilumab in Children Aged ≥ 36 Months to < 12 Years with Atopic Dermatitis: A Case Series. Actas Dermo-Sifiliográficas, Preprints. https://doi.org/10.1016/j.ad.2023.04.042

Chicago

Melgosa Ramos, Fj, T Díaz Corpas, S Martín Jiménez, and A Mateu Puchades. 2024. “Mid-Term Efficacy of Dupilumab in Children Aged ≥ 36 Months to < 12 Years with Atopic Dermatitis: A Case Series.” Actas Dermo-Sifiliográficas, no. Preprints (January). doi:10.1016/j.ad.2023.04.042.